Genmab’s antibody drug conjugate (ADC) rinatabart sesutecan (Rina-S) demonstrated positive efficacy in treating patients with ...

Leerink Partners analysts increased the price target for Genmab A/S (NASDAQ:GMAB) from $29 to $32 and kept an “Outperform” ...

The company's uterine cancer drug is advancing in its development. Quite a few of them also piled into the American ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic ...

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it. The Copenhagen, Denmark, biotechnology company said ...

(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...

Media Release COPENHAGEN, Denmark; May Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the 46th Goldman Sachs Annual ...

Genmab AS (GMAB) reports a robust 19% revenue increase and initiates a share buyback, while navigating geopolitical uncertainties and competitive challenges. May 8, 2025 Copenhagen, Denmark; Interim ...

Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (NASDAQ: GMAB), on the back of encouraging news from the laboratory. Management's disclosure of ...

Management is also assertively conducting a share buyback program. On Monday morning, Genmab announced a set of phase 1/2 clinical trial results for its rinatabart sesutecan (Rina-S) drug ...